REVIEWS
ORIGINAL ARTICLES
Chronic obstructive pulmonary disease (COPD) is associated with pulmonary and systemic inflammation. The latter is likely to contribute significantly to the pathobiology of numerous extrapulmonary effects of the disease, i.e., systemic effects of COPD. The main causes of systemic inflammation in COPD remain to be elucidated. A course of local vs. systemic inflammation is determined by an imbalance between pro- and anti-inflammatory cytokines. Cytokines are fundamental to regulation of the inflammatory process developing in response to an injury. Certain shifts in their homeostasis may lead to a local or systemic disorder. We compared relative contents of pro- and anti-inflammatory cytokines, along with TGF-β levels in bronchoalveolar lavage (BALF) and blood sera from the patients with stable moderate and severe COPD. It has been shown that increased levels of pro-inflammatory mediators were not counterbalanced by an appropriate up-regulation of anti-inflammatory cytokines, both in BALF and peripheral blood of COPD patients, thus causing their altered interrelations. Comparison of levels of these cytokines in BALF and serum did not reveal any direct correlations, thus suggesting that systemic inflammation is not due to mere overflow of inflammatory mediators from the pulmonary tissue, while assuming some other mechanisms that may determine evolvement of this disorder.
Uterine cervical cancer is among the main items of modern oncology. Determination of SCCA levels in blood serum of women with locally disseminated forms of uterine cervical cancer has a great significance for estimation the extent of lesions, tumor progression patterns, as well as treatment monitoring. During our study, we have determined that, before starting a specific treatment, all the patients with locally disseminated forms of cervical cancer had high serum levels of SCCA, along with suppressed anti-tumor immunity.Interestingly, high SCCA levels in blood serum proved to correlate with a decrease in anti-tumor immunity factors in those patients who showed a negative dynamics of tumor progression within one year after the therapy was performed. Meanwhile, the patients with positive post-treatment dynamics exhibited a significant decrease of SCCA levels over a year after therapy, as compared with appropriate pre-treatment values, accompanied by increase in anti-tumor immunity markers in these cases.
SHORT COMMUNICATIONS
In present work, we studied cytokine levels and performed analysis of some immunologic parameters in the patients with chronic lymphocytic leukemia (CLL) before and after treatment with monoclonal anti-CD52 antibody (alemtuzumab). In comparison with a control group, the CLL patients before alemtuzumab treatment showed a significant decrease in relative contents of CD3+ and CD4+ lymphocytes, CD4+/CD8+ T cells, diminished IFNγ and IL-4 levels, and a trend for TNFα increase. After ceasing the alemtuzumab treatment, the patients with CLL exhibited a significant decrease in absolute amounts of mature T-lymphocytes, CD4+, CD8+, CD20+ cells, as well as decreased relative contents of CD16+ lymphocytes. A sufficient post-treatment drop of serum IL-2 concentrations and a trend for serum TNFα and IFNγ decrease were also observed, as compared with pre-treatment values. The changes revealed may be connected with an additional immunosuppressive effect of alemtuzumab. The dynamics of cytokine levels and immunological parameters associated with alemtuzumab treatment is indicative for a weakening of cell-mediated immunity, thus resulting into a potential risk of infectious complications.
OBITUARY
ANNIVERSARY
ISSN 2313-741X (Online)




































